Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus (RSV)

WHO / Ploy Phutpheng

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in young children, accounting for an estimated 3.6 million hospitalizations and approximately 100 000 deaths annually among children under five years of age. Nearly all RSV-related paediatric deaths occur in low- and middle-income countries (LMICs), with infants younger than six months at greatest risk of severe disease and death. Recent advances in RSV prevention,including the development of long-acting monoclonal antibodies and vaccination of pregnant women to protect their infats through maternal antibodies, offer important opportunities to reduce disease burden. However, access remains limited in many settings, particularly for the monoclonal antibodies with currently available product presentations  not fully suited to large-scale implementation in LMIC immunization programmes and high prices limiting availabiliy. Furthermore, treatment options remain extremely limited, with no widely available, effective oral antiviral treatments for young children.  

The WHO Paediatric Drug Optimization exercise for RSV (PADO-RSV), convened in April 2025, identified nirsevimab and clesrovimab as priorities for RSV prevention, emphasizing the need for product presentations aligned with WHO preferred product characteristics, including autodisable administration devices and temperature monitoring. For treatment, ziresovir was prioritized for development in an age-appropriate 10 mg oral formulation, including enteric-coated pellets or alternative dispersible or soluble oral solid dosage forms, while acknowledging limitations in the available clinical evidence and the need for further data to establish its clinical benefit, safety and broader applicability. The PADO watch list includes an investigational long-acting monoclonal antibody and several promising oral antivirals in earlier stages of clinical development, for which further evidence is needed to inform future prioritization. The exercise also highlighted the importance of optimizing clinical trial designs for RSV antivirals, particularly by defining clinically meaningful endpoints, appropriate treatment initiation windows and strategies to ensure the inclusion of children from high-burden settings. These priorities are being taken forward through WHO-led consultations aimed at harmonizing study design approaches and facilitating the generation of evidence to support regulatory approval and WHO policy recommendations.

Portfolio products

5 products · PADO-RSV, since 2026
● Access list: 0    ● Priority list: 3    ● Watch list: 2
0 Access
3 Priority
2 Watch

PADO-RSV priority list 3
Nirsevimaba
Clesrovimaba
aIn a prefilled syringe with an autodisable feature or vial presentation plus autodisable syringe, in addition to a temperature monitor, meeting the WHO preferred product characteristics targets for critical programmatic suitability and access.
Ziresovir 10 mg
(enteric coated pellets in single capsule or alternative oral solid forms that can be dispersed or dissolved)
PADO-RSV watch list 2
TNM001 meeting the WHO preferred product characteristics targets for critical programmatic suitability and access
All oral antiviral agents currently in clinical development (zelicapavir, EDP 323, S-337395, obeldesivir and deuremidevir hydrobromide)

Portfolio Update
  • RSM01: Excluded from the initial priority-setting framework because development was paused following Phase I studies pending a commercial partner. Development has since resumed, with a global Phase 1b clinical trial application submitted in August 2026. [1]
  • TNM001 (retavibart): Approved by China’s National Medical Products Administration in September 2026. [2]
  • Obeldesivir: The RSV clinical development programme was terminated in June 2025 due to lower-than-expected incident rates during the RSV season, which precluded robust assessment of the primary endpoint (symptom reduction). [3]
  • Deuremidevir hydrobromide: Has entered Phase III evaluation in infants and young children in China.
  • Zelicapavir: Has initiated a new Phase IIb paediatric trial, with a registrational Phase IIb/III programme in high-risk adults planned for late 2026.

PADO report

Paediatric drug optimization for respiratory syncytial virus: meeting report, April 2025
This PADO-RSV report outlines tools for the prevention and treatment of respiratory syncytial virus (RSV) in children, focusing on long-acting monoclonal...

Contact

Erin Sparrow
Email: sparrowe@who.int

Yasir Bin Nasir
Email: nisary@who.int

Related publications

WHO position paper on 
immunization to protect 
infants against respiratory 
syncytial virus disease, May 
2025

Recommendations on the use of maternal respiratory syncytial virus (RSV) vaccines and long-acting RSV monoclonal antibodies (mAbs) to prevent severe RSV...

WHO preferred product characteristics of monoclonal antibodies for passive immunization against respiratory syncytial virus (‎RSV)‎ disease

This document describes World Health Organization (WHO) preferences for characteristics of monoclonal antibody (mAb) products used for passive immunization against...

News

[1] SK bioscience. SK bioscience advances development of next-generation infectious disease prevention platform with global Phase 1b CTA submission for RSV preventive antibody candidate [Internet]. 14 Aug 2026. Available from: https://www.skbioscience.com/en/news/news_01_01?id=366&mode=view [cited 2026 Sep 29].

[2] National Medical Products Administration approves retavibart injection for marketing. Beijing: National Medical Products Administration; 2026. Chinese. Available from: https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20260903111247181.html [cited 2026 Sep 17].

[3] Study of obeldesivir to treat nonhospitalized adults with acute respiratory syncytial virus (RSV) infection [Internet]. Bethesda (MD): US National Library of Medicine; 2024. Available from: https://clinicaltrials.gov/study/NCT06585150 [cited 2026 Jan 1].